These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 27708208)

  • 1. Vaccines in prophylaxis of urinary tract infections caused by the bacteria from the genus Proteus.
    Drzewiecka D; Lewandowska G
    Postepy Hig Med Dosw (Online); 2016 Sep; 70(0):1032-1043. PubMed ID: 27708208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction and evaluation of the immune protection of a recombinant divalent protein composed of the MrpA from MR/P fimbriae and flagellin of Proteus mirabilis strain against urinary tract infection.
    Habibi M; Asadi Karam MR; Bouzari S
    Microb Pathog; 2018 Apr; 117():348-355. PubMed ID: 29452195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccines for Proteus mirabilis in urinary tract infection.
    Li X; Mobley HL
    Int J Antimicrob Agents; 2002 Jun; 19(6):461-5. PubMed ID: 12135833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal immunisation with recombinant Lactococcus lactis displaying either anchored or secreted forms of Proteus mirabilis MrpA fimbrial protein confers specific immune response and induces a significant reduction of kidney bacterial colonisation in mice.
    Scavone P; Miyoshi A; Rial A; Chabalgoity A; Langella P; Azevedo V; Zunino P
    Microbes Infect; 2007 Jun; 9(7):821-8. PubMed ID: 17540603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nasal immunization with attenuated Salmonella Typhimurium expressing an MrpA-TetC fusion protein significantly reduces Proteus mirabilis colonization in the mouse urinary tract.
    Scavone P; Umpiérrez A; Maskell DJ; Zunino P
    J Med Microbiol; 2011 Jul; 60(Pt 7):899-904. PubMed ID: 21415205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the administration of cholera toxin as a mucosal adjuvant on the immune and protective response induced by Proteus mirabilis MrpA fimbrial protein in the urinary tract.
    Scavone P; Rial A; Umpierrez A; Chabalgoity A; Zunino P
    Microbiol Immunol; 2009 Apr; 53(4):233-40. PubMed ID: 19714860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Native flagellin does not protect mice against an experimental Proteus mirabilis ascending urinary tract infection and neutralizes the protective effect of MrpA fimbrial protein.
    Scavone P; Umpiérrez A; Rial A; Chabalgoity JA; Zunino P
    Antonie Van Leeuwenhoek; 2014 Jun; 105(6):1139-48. PubMed ID: 24771125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A heterologous prime-boost route of vaccination based on the truncated MrpH adhesin and adjuvant properties of the flagellin from Proteus mirabilis against urinary tract infections.
    Asadi Karam MR; Shirzad AM; Habibi M; Bouzari S
    Int Immunopharmacol; 2018 May; 58():40-47. PubMed ID: 29549718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination immunogenic property of truncated MrpH.FliC as a vaccine candidate against urinary tract infections caused by Proteus mirabilis.
    Bameri Z; Asadi Karam MR; Habibi M; Ehsani P; Bouzari S
    Microb Pathog; 2018 Jan; 114():99-106. PubMed ID: 29138084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination to Protect Against Proteus mirabilis Challenge Utilizing the Ascending Model of Urinary Tract Infection.
    Smith SN; Himpsl SD; Mobley HLT
    Methods Mol Biol; 2019; 2021():201-215. PubMed ID: 31309507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of an intranasal vaccine to prevent urinary tract infection by Proteus mirabilis.
    Li X; Lockatell CV; Johnson DE; Lane MC; Warren JW; Mobley HL
    Infect Immun; 2004 Jan; 72(1):66-75. PubMed ID: 14688082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal immunization with fusion protein MrpH·FimH and MPL adjuvant confers protection against urinary tract infections caused by uropathogenic Escherichia coli and Proteus mirabilis.
    Habibi M; Asadi Karam MR; Shokrgozar MA; Oloomi M; Jafari A; Bouzari S
    Mol Immunol; 2015 Apr; 64(2):285-94. PubMed ID: 25562574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Proteus mirabilis structural fimbrial proteins as antigens against urinary tract infections.
    Pellegrino R; Galvalisi U; Scavone P; Sosa V; Zunino P
    FEMS Immunol Med Microbiol; 2003 May; 36(1-2):103-10. PubMed ID: 12727373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel multi-peptide subunit vaccine admixed with AddaVax adjuvant produces significant immunogenicity and protection against Proteus mirabilis urinary tract infection in mice model.
    Choubini E; Habibi M; Khorshidi A; Ghasemi A; Asadi Karam MR; Bouzari S
    Mol Immunol; 2018 Apr; 96():88-97. PubMed ID: 29525454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the effect of MPL and delivery route on immunogenicity and protectivity of different formulations of FimH and MrpH from uropathogenic Escherichia coli and Proteus mirabilis in a UTI mouse model.
    Habibi M; Asadi Karam MR; Bouzari S
    Int Immunopharmacol; 2015 Sep; 28(1):70-8. PubMed ID: 26033493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with proteus toxic agglutinin, a hemolysin-independent cytotoxin in vivo, protects against Proteus mirabilis urinary tract infection.
    Alamuri P; Eaton KA; Himpsl SD; Smith SN; Mobley HL
    Infect Immun; 2009 Feb; 77(2):632-41. PubMed ID: 19029299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transurethral instillation with fusion protein MrpH.FimH induces protective innate immune responses against uropathogenic Escherichia coli and Proteus mirabilis.
    Habibi M; Asadi Karam MR; Bouzari S
    APMIS; 2016 Jun; 124(6):444-52. PubMed ID: 26918627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of translational fusion of the MrpH fimbrial adhesin-binding domain with the cholera toxin A2 domain, coexpressed with the cholera toxin B subunit, as an intranasal vaccine to prevent experimental urinary tract infection by Proteus mirabilis.
    Li X; Erbe JL; Lockatell CV; Johnson DE; Jobling MG; Holmes RK; Mobley HL
    Infect Immun; 2004 Dec; 72(12):7306-10. PubMed ID: 15557656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucosal vaccination of mice with recombinant Proteus mirabilis structural fimbrial proteins.
    Scavone P; Sosa V; Pellegrino R; Galvalisi U; Zunino P
    Microbes Infect; 2004 Jul; 6(9):853-60. PubMed ID: 15374007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From Catheter to Kidney Stone: The Uropathogenic Lifestyle of Proteus mirabilis.
    Norsworthy AN; Pearson MM
    Trends Microbiol; 2017 Apr; 25(4):304-315. PubMed ID: 28017513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.